Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented
rates of durable clinical responses in patients with various cancer types 1 , 2 , 3 , 4 , 5 . One …

PURPOSE To determine the toxicity, pharmacokinetics, response rate, and response duration
of intravenous (iv) administration of recombinant, humanized anti-p185HER2 monoclonal …

BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600 -mutant
melanoma, but acquired drug resistance is almost universal. We sought to identify the …

Omega-6 (ω-6) polyunsaturated fatty acids (PUFA), abundant in the Western diet, are precursors
for a number of key mediators of inflammation including the 2-series of prostaglandins (…

Purpose Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) blockade with CP-675,206,
a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic …

α-Fetoprotein (AFP) is a self protein expressed by fetal liver at high levels, but is transcriptionally
repressed at birth. AFP is up-regulated in hepatocellular carcinomas, and patients with …

BACKGROUND Hemoglobin increases have been associated with quality of life (QOL)
improvements in anemic cancer patients treated with epoetin alfa, but intervention generally has …

Purpose: An existing immunological paradigm is that high concentrations of soluble protein
contribute to the maintenance of peripheral tolerance/ignorance to self protein. We tested …

This article reviews the immunologic basis of clinical trials that test means of tumor antigen
recognition and immune activation, with the goal to provide the clinician with a mechanistic …

Tumor responses to programmed cell death protein 1 (PD-1) blockade therapy are mediated
by T cells, which we characterized in 102 tumor biopsies obtained from 53 patients treated …